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Abstract: 
Spinal cord injury (SCI) can cause locomotor dysfunctions and sensory deficits. 
Evidence shows that functional nanodrugs can regulate macrophage polarization and 
promote anti-inflammatory cytokine expression, which is feasible in SCI 
immunotherapeutic treatments. Molybdenum disulfide (MoS2) nanomaterials have 
garnered great attention as potential carriers for therapeutic payload. Herein, we 
synthesize MoS2@PEG (MoS2 = molybdenum disulfide, PEG = poly (ethylene 
glycol)) nanoflowers as an effective carrier for loading etanercept (ET) to treat SCI. 
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We characterize drug loading and release properties of MoS2@PEG in vitro and 
demonstrate that ET-loading MoS2@PEG obviously inhibits the expression of 
M1-related pro-inflammatory markers (TNF-α, CD86 and iNOS), while promoting 
M2-related anti-inflammatory markers (Agr1, CD206 and IL-10) levels. In vivo, the 
mouse model of SCI shows that long-circulating ET-MoS2@PEG nanodrugs can 
effectively extravasate into the injured spinal cord up to 96 hours after SCI, and 
promote macrophages towards M2 type polarization. As a result, the ET-loading 
MoS2@PEG administration in mice can protect survival motor neurons, thus, 
reducing injured areas at central lesion sites, and significantly improving locomotor 
recovery. This study demonstrates the anti-inflammatory and neuroprotective 
activities of ET-MoS2@PEG and promising utility of MoS2 nanomaterial-mediated 
drug delivery. 
 
1. Introduction 
Traumatic spinal cord injury (SCI) is a major medical problem worldwide, often 
resulting in motor dysfunction and chronic pain syndrome. Among the 
physiopathological mechanisms involved in the progression of SCI, inflammation is 
one of the most relevant factors. Extensive research has shown that acute 
inflammation, characterized by immune cell activation and inflammatory cytokine 
release, can result in extensive tissue damage, eventually leading to chronic and 
persistent pain syndrome [1]. Accumulating evidence shows that macrophages play 
key cellular roles in inflammatory events [2]. Therefore, regulating inflammation 
through modulating activated macrophages is a promising strategy for SCI treatment 
[3].  
Macrophage activation is associated with distinct macrophage phenotypes, i.e., 
pro-inflammatory (M1) and anti-inflammatory (M2) macrophages. Pro-inflammatory 
M1 macrophages can secrete inflammatory cytokines, such as tumor necrosis factor-α 
(TNF-α), interferon-γ (INF-γ), and interleukins (IL) -2, -6, and -8 [4-6]. However, 
anti-inflammatory M2 macrophages can regulate immune inflammatory reactions, 
  
promote tissue reconstruction, and repair autonomic functions [7]. Therefore, 
blocking M1 macrophage activation pathways and further reprogramming 
macrophages toward M2 phenotypes will be feasible in new immunotherapeutic 
treatments for SCI [5,7]. The current clinical treatment using high-dose 
anti-inflammatory drugs is controversial because of deleterious side effects [8]. Thus, 
it is still a challenge to develop a new anti-inflammatory drug candidate that 
effectively modulates inflammation at SCI sites and minimizes side effects.  
Nanomaterial-based drug carriers are promising candidates for modulating 
inflammation in situ at SCI sites [9-12]. Recent evidence in vitro and in vivo suggests 
that nanoparticles can disrupt vasculatures at SCI sites, and then effectively enhance 
site-specific drug delivery efficacy [13-15]. Two-dimensional (2D) transition metal 
dichalcogenides (TMDs) nanomaterials, e.g., molybdenum disulfide (MoS2), have 
emerged as important segments to construct nanocarriers in drug delivery, because of 
their good biocompatibility and intercalatable structures [16-18]. However, there is no 
relevant report about fabricating MoS2-based nanocarriers for SCI treatments. 
Considering the rich unsaturated-sites of Mo and S on MoS2 surfaces and their 
subsequently strong interactions with cells, MoS2 mediated anti-inflammatory 
macrophage modulations may be effective in SCI treatments, which is presently 
unknown. In this work, the clinical treatment anti-inflammatory drug etanercept (ET), 
considered relatively safe, was chosen to fabricate a new type of nanodrug through 
combining with MoS2 nanosheets. ET is an inhibitor for TNF-α, a key 
anti-inflammatory cytokine immunity regulator [19]. Thus, blocking the activity of 
pro-inflammatory cytokines might be beneficial in SCI treatment because it could 
confer neuroprotection and aid in locomotor recovery [20]. This represents an 
attractive strategy to exploit well-designed MoS2 nanocarrier loading 
anti-inflammatory drugs, such as Trojan Horse for lengthening therapeutic 
time-windows and minimizing high-dose drug administration in SCI treatments.  
In this study, we designed MoS2@PEG nanoflowers evenly integrating poly 
(ethylene glycol) (PEG) with MoS2 nanosheets as feasible nanocarriers for loading the 
anti-inflammatory drug ET (Scheme 1a). The ET-loading MoS2@PEG remarkably 
  
promotes locomotor recovery in mice at post-SCI by inducing an anti-inflammatory 
immune response with M2 macrophage polarization in vivo and in vitro (Scheme 1b). 
More importantly, the time-window for injection at post-injuryis expanded to more 
than 96 hours after ET-loading MoS2@PEG administration, which is of great 
importance in clinical post-SCI treatments. This work presents a novel MoS2 
nanocarrier-mediated drug delivery strategy to selectively modulate 
anti-inflammatory events and promote locomotor recovery in SCI treatments.  
 
2. Experimental section 
2.1. Materials and reagents 
Ammonium heptamolybdatetetrahydrate ((NH4)6Mo7O24·4H2O), thiourea 
(CS(NH2)2), and poly(ethylene glycol)-600 (PEG) were purchased from Sinopharm 
Chemical Reagent Co., Ltd. (Shanghai, China). The recombinant human tumor 
necrosis factor-α receptor IgG Fc fusion protein (rhTNFR:Fc), which was also called 
etanercept (ET), was obtained from Shanghai CP Guojian Pharmaceutical Co., Ltd 
(Shanghai, China). All the other chemicals were of analytical grade and used as 
received without further purification. Primary antibodies, including rabbit anti mouse 
GFAP (ab7260), rat anti mouse F4/80 (ab90247), rabbit anti-Nitric oxide synthase 
(iNOS; ab15323), and mouse anti-Arg1 (ab212522), were all purchased from Abcam 
(Cambridge, MA, USA). Lipopolysaccharides (LPS) from Escherichia coli O111:B4 
was purchased from Sigma-Aldrich (Shanghai, China). All aqueous solutions were 
prepared using ultrapure water (> 18 MΩ). 
2.2 Characterization 
The morphology of nanomaterials was characterized by transmission electron 
microscope (TEM) (JEM-2100F, JEOL). X-ray diffraction (XRD) was performed on 
a Bruker D8 diffractometer, using Cu-Kα radiation (λ = 1.54056 Å). Fourier 
transform infrared spectroscopy (FT-IR) was performed with a Nicolet 6700 FT-IR 
spectrometer. The cell imaging was observed by laser scanning confocal microscope 
(LCM-510, Carl Zeiss). 
  
2.3 Synthesis of ET-loading MoS2@PEG nanoflowers 
The MoS2@PEG nanoflowers were synthesized via a microwave-assisted 
hydrothermal route according to our previous report [21]. Typically, 0.353 g of 
(NH4)6Mo7O24·4H2O, 1.83 g of TU, and 0.06 g of PEG-600 were dissolved in 15 mL 
of distilled water; then the solution was placed in a microwave reactor (Preekem 
MX-8000, Shanghai). After microwave irradiation at 220 
o
C for 10 minutes, the 
as-prepared MoS2@PEG was collected by centrifugation, thoroughly washed with 
distilled water for three times, and dried at 50 
o
C. For drug loading, 50 μg ET was 
first added to 1 mL MoS2@PEG (0.1 mg/mL) and reacted overnight. After reaction, 
the mixture was dialyzed with distilled water for 24 hours using dialysis membrane 
(MW cutoff = 3000); then the synthesized ET-loading MoS2@PEG was re-dispersed 
in 1 mL phosphate-buffered saline (PBS) (pH 7.4), then stored at 4 °C for further use. 
2.4. In vitro study  
2.4.1. Cell culture and MTT assay  
The RAW 264.7 macrophages from mouse and the bone marrow stem cells 
(BMSC) from human were obtained from the Life Science Research Institute of the 
Cell Resource Centre (Shanghai, China). The cells were cultured in the DMEM 
medium supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin in 5% CO2-humidified chamber at 37°C in CO2 incubator (95% 
relative humidity, 5% CO2). 
Cell viability was evaluated by MTT assay. Different types of cells, including 
RAW 264.7 and BMSC, were cultivated in 96-well plates for 24 hours. Subsequently, 
the medium was substituted for fresh medium, supplemented with different 
concentrations of MoS2 nanosheets, MoS2@PEG nanoflowers, and ET-MoS2@PEG, 
respectively. After 24 hours of incubation, cells were washed with PBS (pH 7.4) twice 
and incubated with 0.5 mg/mL 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl 
-2-H-tetrazolium bromide (MTT) reagent at 37 °C for 4 h. The absorbance was 
measured at 490 nm using an absorbance microplate reader.  
2.4.2 Cellular Uptake of MoS2@PEG 
  
Cellular uptakes of nanoparticles were examined by labeling MoS2@PEG by 
green fluorescence protein (GFP). For fabricating GFP-labeled MoS2@PEG, 100 μL 
of GFP (1 mg/mL, DMSO) was added drop by drop to 1 mL of MoS2@PEG solution, 
then reacted in the dark for 6 hours. After reaction, the mixture was dialyzed with 
distilled water for 24 hours using dialysis membrane (MW cutoff = 3000), following 
which GFP-labeled MoS2@PEG was obtained.  
For cell cultures, macrophages were seeded in a 6-well culture plate at a density 
of 1×10
5
 cells/well and allowed to adhere for 24 hours. Then, the old medium was 
replaced by the medium with GFP-labeled MoS2@PEG. After incubation for 2 h at 
37 °C, cells were washed for three times with cell medium, then fixed with 4% 
paraformaldehyde for 20 minutes. For cell staining, cells were incubated with 1 
μg/mL of anti-F4/80 antibody (specific targeting to macrophages) for 1 h and 1 
μg/mL of DAPI (specific targeting to cell nucleus) for 30 minutes at 37 °C. The 
stained cells were washed with PBS (pH 7.4) for three times and observed by 
fluorescence microscope with 488 nm excitation.  
2.4.3. In vitro ET loading and release of MoS2@PEG 
For investigating drug-loading capacity of MoS2@PEG, 1 mL MoS2@PEG (0.1 
mg/mL) was incubated with 50 μg ET overnight. Following incubation, the 
ET-loading MoS2@PEG was centrifuged at 5000 rpm for 10 minutes. The amount of 
ET loaded was calculated by abcam's Etanercept ELISA Kit (ab237643) following the 
manufacturer’s protocol. 
For drug release study, 10 mL of ET-MoS2@PEG solution was placed into 
dialysis membrane (MW cutoff = 3000) and dialyzed against 250 mL of distilled 
water at room temperature. Aliquots of 2.0 mL were withdrawn from the solution at 
different intervals (0, 4, 8, 12, 24, 48, 72, 96, 120 and 144 hours). The volume of 
solution was maintained constantly by adding 2.0 mL of PBS (pH 7.4) after each 
sampling. The amount of ET released from MoS2@PEG was measured using abcam's 
Etanercept ELISA Kit (ab237643) following the manufacturer’s protocol. These 
experiments were repeated for three times and the drug releasing kinetics were plotted 
based on obtained results. In the control group, ET release from MoS2 nanosheets was 
  
examined by fabricating of ET-loading MoS2 nanosheets firstly. For preparing 
ET-loading MoS2 nanosheets, 50 μg ET was first added to 1 mL MoS2 nanosheets 
(0.1 mg/mL) and this mixed solution was reacted overnight. After reaction, the 
mixture was dialyzed with distilled water for 24 hours using dialysis membrane (MW 
cutoff = 3000), and then ET-loading MoS2 nanosheets were obtained. The experiment 
procedure of ET release from MoS2 nanosheets was in accordance with the above.  
2.4.3. Macrophage activation 
Macrophages were activated with lipopolysaccharides (LPS), which is a 
well-known agent for stimulating macrophage activation in vitro and in vivo [22]. 
Briefly, macrophages were cultured at a density of 10
6
 cells/well overnight. 
Macrophages were activated by 100 ng/ml of LPS for 18 hours, and cells were 
washed for three times with cell medium. Subsequently, cells were incubated with 
different agents (ET, MoS2@PEG, and ET-MoS2@PEG) containing media for 6 
hours; then cells were washed for three times with PBS (pH 7.4) and collected for 
cytokine assays.  
2.5. In vivo study 
2.5.1 Contusive SCI model 
Animal experiments were performed according to the Guidelines for the Care 
and Use of Laboratory Animals, which was approved by the Animal Care and Use 
Committee of Jinan University (Guangzhou, China). Adult female C57BL/6J mice 
(7-8 weeks old, weights of 17-22g) were purchased from Guangdong Medical 
Laboratory Animal Center Co., Ltd., and housed in room temperature and humidity 
controlled animal quarters under a 12 hour light/dark cycle. 
The mice were deeply anesthetized by isoflurane vapor (3%). The contusive SCI 
model was constructed using the New York University Impactor equipped for mouse 
contusion surgeries. Spinal cords were exposed by laminectomy at T11-12 levels and 
contused by a 10 g rod dropped at a distance of 6.25 mm. 
2.5.2 Administration of MoS2@PEG and ET-MoS2@PEG 
After 48 hours post SCI, nanomaterials were delivered intravenously in mice via 
the tail vein. The mice (n = 6 ~ 8 animals per experimental group) were transcardially 
  
perfused after post-injections. The spinal cord sections were then saved for genomic 
analysis, histochemical, and immunofluorescent staining. 
2.5.3 Spinal cord tissue processing  
Mice spinal cord tissues were resected after post SCI at 8 weeks. The mice were 
deeply anesthetized with pentobarbital (50 mg/kg), following thoracotomy. Then 30 
mL of normal saline was rapidly perfused through their left ventricles, and 30 mL 4% 
paraformaldehyde was used for fixation. Spinal cord segments of 5 mm in length were 
resected from T11 transition level vertebral of mice and soaked in 4% 
paraformaldehyde for 24 hours. The spinal cord segments were transferred into 30% 
sucrose solution before the tissues sank. Finally, the tissues were cut into 20 µm 
sections after freezing. 
2.5.4 Assessment of locomotor capacity and motor evoked potential (MEP) 
detection 
Locomotion recovery after SCI was scored according to the Basso Mouse Scale 
(BMS) [23] and CatWalk-assisted gait analysis [24]. Two independent examiners 
blinded to the treatment regimen assessed hind limb movements. 
Motor evoked potential (MEP) testing was carried out by electromyography on 
post-SCI mice. A stimulation electrode was applied to the rostral ends of their surgical 
spinal cords and the recording electrode was placed in their biceps flexor cruris. A 
single square wave stimulus was 0.5 mA, 0.5 ms in duration, 2 ms time delay, and 1 
Hz. The amplitude was measured from the initiation point of the first response wave 
to its highest point. 
2.5.5 Acute toxicity experiments 
After administration of MoS2@PEG and ET-MoS2@PEG, the treated-mice in 
different groups were sacrificed after 21 days. The organs, including heart, liver, 
spleen, lungs, and kidneys, were acquired, fixed with formalin, embedded with 
paraffin, and sectioned. 0.8 mL of blood samples was collected from each mouse to 
conduct blood analysis and serum biochemistry assay. 
2.5.6 Nanoparticle extravasation study 
  
At different time points (24, 48, and 96 hours and 1 week), the mice were 
intravenously administered a 200 μL GFP-labeled MoS2@PEG. They were then 
sacrificed after nanomaterial injection. Spinal cords were dissected out and postfixed 
overnight in 4% PFA in PBS and, subsequently, in 30% sucrose solution in PBS for 
48 hours for cryoprotection, after which spinal cords were frozen and prepared for 
cryosection. 
2.5.7 Histology and immunohistochemistry 
The 20 μm-thick serial frozen sections of spinal cords were stained with 0.1% 
cresyl violet to image tissue morphology. The 5 μm-thick paraffin sections of organ 
tissues were stained with Hematoxylin and Eosin (H&E) staining solution. For 
imunohistochemistry, the RAW 264.7 cells were fixed with 4% paraformaldehyde 
and permeabilized by 0.2% Triton X-100 (Sigma-Aldrich). Staining was carried out 
by overnight with the primary antibodies, including anti-F4/80 (1:1000, ab90247), 
anti-CD11b (1:200, ab8878), anti-CD11c (1:200, ab11029), anti-CD206 (1:200, 
ab64693), anti-iNOS (1:100, ab15323), anti-Arg1 (1:100, ab212522), and 
anti-GFAP(1:1000, ab7260). For fluorescent imaging, fluorescent Alexa Fluor 488 or 
546 secondary antibodies (1:1000, Invitrogen) were used for staining at room 
temperature for 2 h. After PBS washing, the tissue slices were fixed with Vectashield 
containing DAPI and used for fluorescent imaging. Inverted fluorescence microscope 
(Axio Observer A1, carl zeiss, Germany) was used for imaging and fluorescence 
analysis.  
2.5.8 Spinal cord tissue immunofluorescence  
Briefly, the mice were anesthetized using pentobarbital (50 mg/kg) and perfused 
with 0.1 M PBS, followed by 4% PFA. After a laminectomy, a 10 mm segment at T11 
vertebrae was cut and the tissue samples were quickly frozen in an ethanol-dry ice 
bath. Samples were then stored at -80°C, and homogenized in a 200 μL ice-cold Cell 
Lysis Buffer (Beyotime, China) containing enzyme inhibitors. Subsequently, the 
samples were centrifuged at 10,000 g for 10 minutes at 4 °C, after which, the 
supernatants were frozen at -80 °C. Protein levels were then determined using 
bicinchoninic acid (BCA) protein assay (Beyotime, China).  
  
The spinal cords from mice were analyzed with the Bio-Plex system (Bio-Rad, 
Hercules, CA) using a 23-plex cytokine array kit, including Eotaxin, G-CSF,  
GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12, IL-12, 
IL-13, IL-17A, KC, MCP-1 (MCAF), MIP-1α, MIP-1β, RANTES, and TNF-α. 
2.5.9 Pathology analysis 
Mice were sacrificed, and tumors were set in 4% paraformaldehyde solution for 
fixing, set in paraffin, and stained with hematoxylin and eosin (H&E). The slice was 
examined with an inverted luminescence microscope (OLYMPUS X73, Japan). 
2.6 Statistical analysis  
Data were expressed as mean ± standard deviation for at least three independent 
experiments. The Student’s t test was used to assess the significance between 
experimental and control groups. Values were considered significant at p < 0.05.  
3. Results and discussion 
3.1. ET-loading MoS2@PEG nanoflowers synthesis and characterization  
In this study, the MoS2@PEG nanocomposites were synthesized via a 
microwave-assisted hydrothermal process (Scheme 1a). Regarding the abundant PEG 
in the MoS2@PEG and its rich ether and hydroxyl groups, ET could be combined on 
nanoflower surfaces through noncovalent approach (e.g., hydrogen bonds, van der 
Waals force, etc.). Such weak interactions were beneficial for the release of ET during 
treatments. As observed in TEM image (Figure 1a), the synthesized MoS2@PEG 
presented a size of 200 - 300 nm. Closer observation showed that the nanocomposite 
had a flower-like structure, and its visible lattice fringes were measured at 0.27 nm 
(Figure 1b), which could be indexed as the (100) or (010) of hexagonal MoS2. This 
result was in good accordance with XRD analysis (Figure 1c). Collectively, TEM 
image validated that MoS2@PEG nanoflowers consisted of multi-layers of MoS2 
nanosheets. The FT-IR spectrum showed the absorption bands associated with vO-H 
(3413 cm
-1
), vC=S (1400 cm
-1
) and δN-H (619 cm
-1
) (Figure 1d), identifying the 
presence of PEG in the composites. Noticeably, the obvious vO-H band indicated the 
rich hydroxyl groups on MoS2@PEG surfaces, which were absent on bare MoS2 
nanosheets.  
  
We next investigated the ET-loading capacity of MoS2@PEG nanoflowers and 
bare MoS2 nanosheeets. As shown in Figure 1e, ET loading on MoS2@PEG was 
significantly higher (~60% of total ET added) compared with the MoS2 nanosheets 
(~30% of total ET addition). This suggested that the flower-like nanostructure had a 
higher drug loading capacity, which was an additional advantage of our technique. 
Furthermore, their releasing kinetics was shown in Figure 1f. Visibly, the 
MoS2@PEG displayed a slower rate of ET release; only ~45% of the drug was 
released after 24 hours, and almost 100% was after 144 hours. By contrast, the MoS2 
nanosheets released ~60% ET in the first 12 hours and ~80% after 24 hours, while 
almost 100% after 75 hours (Figure 1f). As for the MoS2@PEG, the relatively rapid 
release observed in the initial period could be attributed to the diffusion of ET loaded 
on nanosheet surfaces. Subsequently, the slower release after 24 hours was ascribed to 
this building-block structure, in which drugs were entrapped between layers of MoS2 
nanosheets. Therefore, this nanoflower structure of MoS2@PEG and weak 
noncovalent interactions with ET provided a facile strategy to tune the drugs’ 
releasing capabilities.  
3.2. In vitro cell viability and in vivo toxicity evaluation  
To meet the requirements of biomedical application, it was essential to examine 
the toxicity of the nanocarriers. The cell viabilities of MoS2 nanosheets, MoS2@PEG, 
ET, and ET-MoS2@PEG at different concentrations were evaluated using different 
cell lines (including RAW 264.7 and BMSC), respectively. As shown in Figure 2, the 
low level of cytotoxixity (~90% cell viability) was observed for MoS2 nanosheets, 
MoS2@PEG, and ET-MoS2@PEG, respectively, when their concentrations were 150 
μg/mL. This suggested that the MoS2@PEG had good biocompatibility, attributing to 
the satisfactory biocompatibility of MoS2 nanosheets and PEG, which was crucial for 
efficient in vivo drug delivery. Simultaneously, both ET and ET-loading MoS2@PEG 
showed low cytotoxicity to cells (Figure 2), indicating the anti-inflammatory drug ET 
was safe for fabricating nanodrugs. No significant in vitro cytotoxicity was observed 
for ET-MoS2@PEG concentrations of 10-150 μg/mL. Therefore, this noncovalent 
drug loading approach proved synthetically advantageous because it was typically 
  
achieved via comparatively simple procedures that required fewer chemical reagents, 
thus reducing the potential for toxicity problems for clinical applications [25,26]. The 
ET-loading MoS2@PEG concentration of 150 μg/mL, for which no direct cytotoxic 
effects were observed, was higher than locally administered doses in in vivo 
experiments (100 μg/mL, see below). 
In vivo experiments included hematoxylin and eosin (H&E) staining and blood 
biochemistry analysis; they were also conducted to ensure the safe application of 
MoS2@PEG and ET-MoS2@PEG. As shown in Figure 3a, the H&E staining showed 
no obvious tissue damage in the main organs, and significant parameters of blood 
hematology and biochemistry analysis also indicated no noticeable changes (Figure 
3b), in comparison with that of the control groups. Preliminary results provided that 
MoS2@PEG had low toxicity to our dose tested in mice. The reason for lower toxicity 
of MoS2@PEG was ascribed to the biocompatible constituents contained in MoS2 and 
PEG, and their mild synthesis conditions free from toxic organic solvents and 
chemicals. In addition, the smaller size of as-prepared MoS2@PEG facilitated its body 
clearances, which may reduce long-term toxicity and could prove beneficial in further 
bio-applications.  
3.3. In vitro cellular uptake and anti-inflammatory activity of ET-MoS2@PEG  
Cellular uptake is one of the important entry mechanisms for extracellular 
materials, particularly nanomaterials [27,28]. In this study, the localization of 
MoS2@PEG in macrophages was investigated by using different fluorescence labels, 
including F4/80 (red fluorescence, specific targeting to macrophages), DAPI (blue 
fluorescence, specific targeting to cell nucleus), and green fluorescence protein (GFP) 
(green fluorescence, specific tagged on MoS2@PEG). Analysis from fluorescence 
imaging and flow cytometry clearly showed that a larger number (~95.04%) of 
MoS2@PEG entered into macrophages through cellular uptake approach (Figure 4), 
which was of great importance to load drugs into SCI sites. This was due to the 
smaller size of synthesized nanocarriers, which benefited cellular uptake and 
internalization. 
It is known that SCI can induce high expression of TNF-α, a pro-inflammatory 
  
cytokine, which is a key regulator of macrophage polarization [29]. As an effective 
TNF-α inhibitor, the ET-loading MoS2@PEG is expected to regulate macrophage 
polarization and further inhibit pro-inflammatory marker expression. It is well-known 
that LPS is a potent activator of macrophages and is commonly used to activate cells 
in vitro and in vivo [22]. Therefore, macrophage activation was induced by treatment 
with LPS for 6 hours, which created an inflammatory environment in vitro. After 
treating macrophages with LPS, cells were incubated with MoS2@PEG and 
ET-MoS2@PEG for 2 hours to measure the expressions of pro-/anti-inflammatory 
markers, respectively. Under cell fluorescence imaging, it showed that MoS2@PEG 
did not induce the up-regulation of anti-inflammatory (Figure 5a) or pro-inflammatory 
markers (Figure 5b), compared with PBS group. In contrast, introducing 
ET-MoS2@PEG obviously led to a lower expression of nitric oxide synthase (iNOS, a 
classical pro-inflammatory M1 macrophage marker) (Figure 5a), while it promoted a 
higher expression of arginase 1 (Arg-1, a classical anti-inflammatory M2 macrophage 
marker) (Figure 5b). This indicated that ET-MoS2@PEG could induce 
anti-inflammatory M2 macrophage polarization. We further used F4/80 and CD11b to 
double-label the macrophages, and then investigated the anti-inflammatory activity of 
ET-MoS2@PEG in vitro. The double positive macrophage (F4/80
+
, CD11b
+
) 
polarization of M1/M2 was characterized, and the expressions of M1 and M2 markers 
were measured by flow cytometry. As shown in Figure 5c-e, low expression of 
CD11c (M1 marker) was detected in ET and ET-MoS2@PEG groups, compared to 
PBS and MoS2@PEG groups; however, the ET and ET-MoS2@PEG groups 
significantly increased the expression of CD206 (M2 marker). Similarly, the analysis 
from quantitative real-time polymerase chain reaction (RT-PCR) also revealed that 
ET-MoS2@PEG down-regulated the expression of M1-related TNF-α, CD86, and 
iNOS markers (Figure 5f), while the expression of M2-related Agr1, CD206 and 
IL-10 markers were obviously up-regulated (Figure 5g), compared with MoS2@PEG. 
Collectively, these results demonstrated the anti-inflammatory potential of 
ET-MoS2@PEG in vitro, resulting in M2 macrophage polarization.  
  
3.4. In vivo time dependency of ET-MoS2@PEG post-SCI  
Adult female mice (C57/BL6) were subjected to a clinically relevant contusion 
SCI at the thoracic-11 (T11) vertebral level, using a force-controlled impaction device. 
To determine the permeability of injured spinal cords to MoS2@PEG as a function of 
time post-injury, we intravenously injected a nanoparticle cocktail comprised of 
GFP-labeled ET-MoS2@PEG, and then fluorescence imaging was observed at 
different times post-injury (24, 48, 96 hours and 1 week). As shown in Figure 6, 
MoS2@PEG extravasates into injured spinal cords after 24, 48, and 96 hours 
post-injury, respectively. The reason for MoS2@PEG entering into SCI sites was 
attributed to the breakdown of blood-spinal cord barriers (BSCB) [14], which helped 
nanomaterials leaking into injured spinal cords. However, at 1 week post-injury, very 
few nanomaterials were observed in spinal cord tissues (Figure 6d). This indicated 
that long-circulating drug nanocarriers, such as ET-MoS2@PEG, could achieve 
efficient drug deliveries even at a 96-hour post-injury time-window. This 
demonstrated that MoS2@PEG nanoflowers of 200-300 nm in diameter could 
extravasate into injured spinal cord parenchyma up to 96 hours post-SCI, but not 
beyond the 1st week post-SCI, which was much longer than the 8 h therapeutic 
time-window for clinical methylprednisolone (MP) alone. This result showed that 
using long-circulating nanocarriers such as MoS2 nanocomposites could achieve drug 
deliveries up to 96 hours post-SCI through passive targeting.  
3.5. In vivo M1/M2 macrophage polarization and quantitative inflammatory 
cytokine analysis after ET-MoS2@PEG administration 
Macrophages play the important roles in the innate immune responses and, 
subsequently, tissue repair activities after SCI [30]. Post-injury tissue repair involves 
regulation of the balance between two major populations of macrophages, including 
pro-inflammatory M1 and anti-inflammatory M2 macrophages [31]. The M1/M2 ratio 
is an important factor in SCI repair. M1 macrophages are neurotoxic, while M2 
macrophages can promote axonal regeneration after injury [32]. In order to investigate 
the effects of ET-MoS2@PEG on macrophage polarization, spinal sections from the 
  
1st week post-SCI, mice were characterized using immunofluorescence assay (Figure 
7a). Figure 7 presented the changes of local M1/M2 subsets in injured spinal cords in 
vivo. It showed that the ratio of iNOS
+
/F4/80
+
 (M1 macrophage marker) was 
significantly decreased in ET-MoS2@PEG group, while the ratio of Arg1
+
/F4/80
+
 
cells (M2 macrophage marker) was significantly increased (Figure 7b), when 
compared with the control groups of ET and MoS2@PEG. In vivo, ET group showed 
a lower expression of anti-inflammatory cytokines, in comparison with in vitro 
anti-inflammatory experiments (Figure 5), which was ascribed to the knowledge that 
drug molecules were metabolized after blood circulation, and fewer drug molecules 
could reach injured spinal cords, as shown in the SCI mouse model. These results 
suggested that ET-MoS2@PEG nanodrugs increased the numbers of M2 macrophages 
in injured SCI, while reducing the numbers of M1 macrophages; this contributed to 
modulating inflammatory milieu to a hybrid, anti-inflammatory state.  
To assess the expression of inflammation related cytokines, we performed 
cytokine gene analysis on the spinal cords of the control or ET-MoS2@PEG-treated 
mice after SCI (Figure 8a). After constructing the model for spinal cord contusions, 
the mice were treated with PBS, ET, MoS2@PEG, and ET-MoS2@PEG for 24 hours 
post-SCI, respectively. As shown in Figure 8b, anti-inflammation-associated 
transcripts, especially interleukins-4 (IL-4) and interleukins-10 (IL-10), were 
up-regulated on spinal cords of ET-MoS2@PEG-treated mice after SCI, compared 
with controlled groups. However, pro-inflammation-associated transcripts, including 
TNF-α, IFN-γ, IL-1α, and IL-6, monocyte chemotactic protein 1 (MCP-1), and 
macrophage inflammatory protein-1β (MIP-1β), were down-regulated after 
ET-MoS2@PEG treatment, as shown in SCI model (Figure 8b). Therefore, these 
results indicated that ET-MoS2@PEG administration could lead to a hybrid, 
anti-inflammatory condition comprising both promotion of anti-inflammatory 
cytokine expressions and, simultaneously, inhibition of pro-inflammatory cytokines 
levels. These results were consistent with anti-inflammatory activity of 
ET-MoS2@PEG in vitro.  
 
  
3.6. In vivo locomotor recovery and neuroprotective effects  
To further assess locomotor recovery of ET-MoS2@PEG-treated mice after SCI, 
we measured by a Basso Mouse Scale (BMS) in an open field and analyzed the 
CatWalk-assisted gait. After constructing a mice model for spinal cord contusions, the 
mice were treated with PBS, ET, MoS2@PEG, and ET-MoS2@PEG at 48 hours 
post-SCI, respectively. After traumatic SCI, motor behavior was assessed by BMS in 
an open field. Complete hindlimb paralysis (BMS score = 0) was observed for all four 
groups at 1 day post-injury. As shown in Figure 9a, the ET-MoS2@PEG-treated mice 
exhibited significant improvement in the BMS score (BMS score = 4) at 2-8 weeks 
post-injury, when compared with control group. Furthermore, the score from the 
regularity index in ET-MoS2@PEG-treated group was 80 after 8 weeks post-injury 
(Figure 9b), which was higher than that of ET-treated group. 
The CatWalk analysis also showed that the hind maximal contact area after 
ET-MoS2@PEG treatment was enlarged in 0.12 cm
2
, in comparison with 0.08 cm
2
 of 
the ET group (Figure 9c), indicating a significant recovery of hind-limb functions in 
mice. We further recorded electromyography with a biceps femoris after 8 weeks 
post-SCI. It showed that the amplitudes of motor-evoked potential (MEP) were 
significantly higher in ET-MoS2@PEG group (3 mV) than in control groups (Figure 
9d).  
To further verify the neuroprotective effects of ET-MoS2@PEG, we performed 
a histological injury study in 8-week post-SCI mice, and the spinal cord tissues were 
stained using anti-glial fibrillary acidic protein (GFAP) immunostaining. The 
ET-MoS2@PEG-treated mice had lower injured areas at central lesion sites (Figure 
10a), in comparison with the control group, while no notable differences were 
observed at other regions. Additionally, we stained the neurons with Nissal staining 
and counted the number of survival motor neurons, as they were responsible for 
locomotor functions of post-SCI [33]. In comparison with the control groups, a higher 
number of survival motor neurons were observed on the ET-MoS2@PEG-treated 
group (Figure 10b). In its entirety, these results demonstrated that the activity of 
ET-MoS2@PEG was beneficial in SCI treatments because they could provide 
  
neuro-protection and aid in locomotor recovery in vivo.  
 
4. Conclusions 
In conclusion, the ET-MoS2@PEG nanoflowers have been successfully 
synthesized as nanodrugs to achieve anti-inflammatory and neuroprotective activities 
after SCI in vivo and in vitro. After introducing PEG, MoS2 nanosheets could 
self-assemble into nanoflowers, exhibited slower drug release, higher payloading 
capacity, good biocompatibility, and long drug circulation in SCI sites. In vitro study 
suggested that MoS2@PEG nanoflowers were efficient and safe as drug nanocarriers 
to realize anti-inflammatory macrophage-modulating SCI immunotherapy. Both in 
vitro and in vivo studies demonstrated that MoS2@PEG as nanodrugs were capable of 
up-regulating anti-inflammatory marker expressions via regulating macrophage 
polarization into anti-inflammatory M2 phenotypes. In vivo, the mouse model of SCI 
showed that ET-MoS2@PEG nanodrugs could extravasate into the injured spinal cord 
parenchyma up to 96 hours post-SCI, significantly prolonging the time-window for 
therapy [11,34]. Importantly, anti-inflammatory ET-MoS2@PEG treatments could 
provide neuro-protection and correspondingly help locomotor recovery, as shown in 
the mouse model. This study demonstrated the potential of ET-loading MoS2@PEG 
nanodrugs in SCI immunotherapy.  
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Figure legends 
 
Scheme 1. Schematic illustration for (a) the preparation of ET-MoS2@PEG 
nanoflowers, and (b) their modulated anti-inflammation macrophage in SCI treatment.  
Figure 1. Nanostructure characterization and drug delivery of MoS2@PEG 
nanocomposites. (a) low resolution TEM image, (b) high resolution TEM image, (c) 
XRD pattern, (c) FT-IR spectra, (d) ET loading on MoS2@PEG and MoS2 nanosheet 
(n = 3), and (e) In vitro release profiles of ET from MoS2 nanosheet and MoS2@PEGs 
in PBS (pH 7.4) (n = 8). 
Figure 2. In vitro cell viabilities of MoS2 nanosheets, MoS2@PEGs, ET, and 
ET-MoS2@PEGs. (a,b) MTT assay of mouse macrophage cell (RAW 264.7) after 
incubated with different concentrations of nanomaterials (n = 3). (c,d) MTT assay of 
bone marrow stem cells (BMSC) after incubated with different concentrations of 
nanomaterials (n = 8).  
Figure 3. In vivo toxicity evaluation. (a) H&E-stained slice images of major organs, 
and bars with different characteristics are statistically different at the P < 0.05 level. 
(b) Blood biochemistry data including white blood cells (WBC), red blood cells 
(RBC), platelets (PLA), Alanine aminotransferase (ALT), aspartate transaminase 
(AST) and blood urea nitrogen (BUN). (n=8 mice/group). 
Figure 4. In vitro cellular uptake of MoS2@PEG on macrophages. Fluorescence 
imaging of (a) DAPI (blue fluorescence), (b) F4/80 (red fluorescence), (c) 
GFP-labeled PEG@MoS2 (green fluorescence), (d) the merging fluorescence. 
Fluorescence quantitative analysis by flow cytometry (e). Scale is 100 μm. 
Figure 5. In vitro anti-inflammatory activity of ET-MoS2@PEG on LPS-mediated 
activated macrophages. (a) Fluorescence imaging showed MoS2@PEG administration 
induced low expression of M1-related pro-inflammatory marker. Scale is 50 μm. (b) 
Fluorescence imaging showed MoS2@PEG administration induced high expression of 
M2-related anti-inflammatory marker. (c-e) Flow cytometry analysis for the 
expression of CD11c (mark of M1) and CD206 (mark of M2) on macrophage (F4/80
+
, 
CD11b
+
) (n = 8). (f, g) RT-PCR quantitative analysis of M1 and M2 macrophage 
  
marker expression on activated macrophages (n = 8). *, P < 0.05; **, P < 0.01; ***, P 
< 0.001. 
Figure 6. In vivo ET-MoS2@PEG extravasation is dependent on time post-SCI. 
Fluorescence imaging of injured spinal cord at 24 hours (a), 48 hours (b), 96 hours (c) 
and 1 week (d) post-injury.  (n=6 mice/group). 
Figure 7. In vivo M1/M2 macrophage polarization after ET-MoS2@PEG 
administration. (a,b) Spinal sections from the mice after 1 week post-SCI were 
immunostained with anti-F4/80 (red, a generic marker for macrophages), anti-iNOS 
(green, a maker for M1 macrophages) and anti-Arg1 (green, a maker for M2 
macrophages). Scale bar 100 µm, ***P < 0.001. Means ± SEM. (n = 6 mice/group). 
Figure 8. In vivo quantitative inflammatory cytokine analysis. (a) Pro-inflammatory 
cytokines in spinal samples were analyzed using the luminex analysis system 
(Bio-Rad, Hercules, CA) at 24 hours after SCI. Different colors indicated the protein 
levels from low (blue) to high (red) representing the fold change. (b) ET-MoS2@PEG 
treatment significantly increased anti-inflammatory markers IL-4 and IL-10 levels, 
while decreased pro-inflammatory markers such as TNF-α, IFN-γ, IL-1α, IL-6, 
MCP-1, and MIP-1β. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (n = 6 mice/group). 
Figure 9. In vivo locomotor recovery after ET-MoS2@PEG administration. (a) BMS 
scores at different time-points after spinal cord contusion (n=8 mice/group). (b) 
Regularity Index at different time-points. (c) Hind Max Contact Areas were analyzed 
using the CatWalk XT automated quantitative gait analysis system (n=8 mice/group). 
(d) Examples and the statistic histogram of motor-evoked potential (MEP) recordings 
from mice 8 weeks post-surgery (n=8 mice/group), *, P < 0.05; ***, P < 0.01. 
Figure 10. ET-MoS2@PEG reduced damaged area and protected neurons after SCI. (a) 
Representative injury sites labeled with anti-GFAP antibodies and the statistic 
histogram of lesion volumes in different groups (n=8 mice per group; Scale bar: 500 
µm). (b) Survival of motor neurons immunostained with Nissl staining in the spinal 
cord ventral horn (VH) at the 8 week after SCI. (n=8 mice/group; Scale bar: 50 µm). *, 
P < 0.05; ***, P < 0.001. 
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